EDNRA and metabolic disease: Our present study showing that both ETAR and ETBR antagonists could block ET-1 growth signals in visceral and subcutaneous HWPs supports the possible use of these antagonists in controlling the number of fat cells and their potential applications in fat cell-associated obesity and other metabolic disorders.